Wird geladen...

Pegylated Interferon for the Adjuvant Treatment of Melanoma: FDA Approved, but What Is Its Role?

The article by Herndon and colleagues on the approval of peginterferon-alfa-2b for the adjuvant treatment of patients with resected node-positive melanoma, published in this issue of The Oncologist, is examined, and the relevance of this therapy in clinical practice discussed.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sondak, Vernon K., Kudchadkar, Ragini
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2012
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3481887/
https://ncbi.nlm.nih.gov/pubmed/23002125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0368
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!